Current Progress in Treating Systemic Lupus Erythematosus Using Exosomes/MicroRNAs.

Area of Science:

• Immunology
• Regenerative Medicine
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant patient impact.
• Current SLE therapies often cause adverse reactions and exhibit limited efficacy due to clinical heterogeneity.
• Mesenchymal stromal cells (MSCs) possess immunomodulatory and tissue repair properties beneficial for autoimmune conditions.

Purpose of the Study:

• To review the therapeutic applications of MSCs and their derived exosomes in treating SLE.
• To highlight the role of microRNAs (miRNAs) delivered by MSC-derived exosomes in SLE.
• To assess the potential of MSCs and exosomes as future therapeutic strategies for SLE and other autoimmune diseases.

Main Methods:

• Review of existing literature on MSCs from various sources (bone marrow, adipose, umbilical cord, synovial, gingival) for SLE treatment.
• Analysis of studies focusing on exosomes and miRNAs derived from MSCs in the context of SLE.
• Examination of clinical data regarding MSC infusion efficacy in SLE patients.

Main Results:

• MSCs and their secreted exosomes demonstrate significant potential in managing SLE.
• Exosomes, particularly their miRNA cargo, play a crucial role in the therapeutic effects of MSCs on SLE.
• MSC-derived exosomes are being explored as advanced drug delivery vectors for autoimmune diseases.

Conclusions:

• MSCs and their exosomes represent a promising therapeutic avenue for systemic lupus erythematosus.
• The immunomodulatory and regenerative properties of MSC-derived exosomes offer a novel approach to SLE treatment.
• Further research into MSC-derived exosomes and miRNAs could lead to improved therapies for SLE and other autoimmune disorders.